These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 28448160)
1. Validation of ANAM for cognitive screening in a mixed clinical sample. Vincent AS; Roebuck-Spencer TM; Cox-Fuenzalida LE; Block C; Scott JG; Kane R Appl Neuropsychol Adult; 2018; 25(4):366-375. PubMed ID: 28448160 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of the ANAM General Neuropsychological Screening Battery (ANAM GNS) for detecting neurocognitive impairment in a mixed clinical sample. Woodhouse J; Heyanka DJ; Scott J; Vincent A; Roebuck-Spencer T; Domboski-Davidson K; O'Mahar K; Adams R Clin Neuropsychol; 2013; 27(3):376-85. PubMed ID: 23368639 [TBL] [Abstract][Full Text] [Related]
3. Initial clinical validation of an embedded performance validity measure within the automated neuropsychological metrics (ANAM). Roebuck-Spencer TM; Vincent AS; Gilliland K; Johnson DR; Cooper DB Arch Clin Neuropsychol; 2013 Nov; 28(7):700-10. PubMed ID: 23887185 [TBL] [Abstract][Full Text] [Related]
4. Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. Roebuck-Spencer TM; Yarboro C; Nowak M; Takada K; Jacobs G; Lapteva L; Weickert T; Volpe B; Diamond B; Illei G; Bleiberg J Arthritis Rheum; 2006 Jun; 55(3):434-41. PubMed ID: 16739211 [TBL] [Abstract][Full Text] [Related]
5. Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. Brunner HI; Ruth NM; German A; Nelson S; Passo MH; Roebuck-Spencer T; Ying J; Ris D Arthritis Rheum; 2007 Oct; 57(7):1174-82. PubMed ID: 17907235 [TBL] [Abstract][Full Text] [Related]
6. Test-retest reliability and practice effects for the ANAM General Neuropsychological Screening battery. Vincent AS; Roebuck-Spencer TM; Fuenzalida E; Gilliland K Clin Neuropsychol; 2018 Apr; 32(3):479-494. PubMed ID: 28832273 [TBL] [Abstract][Full Text] [Related]
7. Validity Evidence for the Use of Automated Neuropsychologic Assessment Metrics As a Screening Tool for Cognitive Impairment in Systemic Lupus Erythematosus. Tayer-Shifman OE; Green R; Beaton DE; Ruttan L; Wither JE; Tartaglia MC; Kakvan M; Lombardi S; Anderson N; Su J; Bonilla D; Zandy M; Choi MY; Fritzler MJ; Touma Z Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1809-1819. PubMed ID: 31628718 [TBL] [Abstract][Full Text] [Related]
9. Assessing change with the Automated Neuropsychological Assessment Metrics (ANAM): issues and challenges. Roebuck-Spencer T; Sun W; Cernich AN; Farmer K; Bleiberg J Arch Clin Neuropsychol; 2007 Feb; 22 Suppl 1():S79-87. PubMed ID: 17118623 [TBL] [Abstract][Full Text] [Related]
10. Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Godefroy O; Fickl A; Roussel M; Auribault C; Bugnicourt JM; Lamy C; Canaple S; Petitnicolas G Stroke; 2011 Jun; 42(6):1712-6. PubMed ID: 21474808 [TBL] [Abstract][Full Text] [Related]
11. Automated neuropsychological assessment metrics (ANAM) and Woodcock-Johnson III Tests of Cognitive Ability: a concurrent validity study. Jones WP; Loe SA; Krach SK; Rager RY; Jones HM Clin Neuropsychol; 2008 Mar; 22(2):305-20. PubMed ID: 17853133 [TBL] [Abstract][Full Text] [Related]
12. Cognitive dysfunction in SLE: development of a screening tool. Adhikari T; Piatti A; Luggen M Lupus; 2011 Oct; 20(11):1142-6. PubMed ID: 21676920 [TBL] [Abstract][Full Text] [Related]
13. Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. Hanly JG; Omisade A; Su L; Farewell V; Fisk JD Arthritis Rheum; 2010 May; 62(5):1478-86. PubMed ID: 20155829 [TBL] [Abstract][Full Text] [Related]
14. Automated neuropsychological assessment metrics (ANAM) measures of cognitive effects of Alzheimer's disease. Levinson D; Reeves D; Watson J; Harrison M Arch Clin Neuropsychol; 2005 May; 20(3):403-8. PubMed ID: 15797175 [TBL] [Abstract][Full Text] [Related]
15. The use of ANAM to assess the side-effect profiles and efficacy of medication. Wilken JA; Sullivan CL; Lewandowski A; Kane RL Arch Clin Neuropsychol; 2007 Feb; 22 Suppl 1():S127-33. PubMed ID: 17116387 [TBL] [Abstract][Full Text] [Related]
16. Identifying and monitoring cognitive deficits in clinical populations using Automated Neuropsychological Assessment Metrics (ANAM) tests. Kane RL; Roebuck-Spencer T; Short P; Kabat M; Wilken J Arch Clin Neuropsychol; 2007 Feb; 22 Suppl 1():S115-26. PubMed ID: 17101258 [TBL] [Abstract][Full Text] [Related]
17. Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools (CNTs): Reliability and Validity for the Assessment of Sport-Related Concussion. Nelson LD; LaRoche AA; Pfaller AY; Lerner EB; Hammeke TA; Randolph C; Barr WB; Guskiewicz K; McCrea MA J Int Neuropsychol Soc; 2016 Jan; 22(1):24-37. PubMed ID: 26714883 [TBL] [Abstract][Full Text] [Related]
18. The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Wilken JA; Kane R; Sullivan CL; Wallin M; Usiskin JB; Quig ME; Simsarian J; Saunders C; Crayton H; Mandler R; Kerr D; Reeves D; Fuchs K; Manning C; Keller M Mult Scler; 2003 Mar; 9(2):119-27. PubMed ID: 12708806 [TBL] [Abstract][Full Text] [Related]